塞妥珠单抗聚乙二醇治疗中轴型脊柱关节炎改善工作场所与家庭生产力:III期研究至第96周结果
RAPID-axSpA是一项III期双盲安慰剂对照试验,325例中轴型脊柱关节炎患者按1:1:1随机接受安慰剂、塞妥珠单抗聚乙二醇200 mg每2周或400 mg每4周。至第24周,塞妥珠单抗聚乙二醇组较安慰剂组每月缺勤减少1.0天 vs 0.4天,假性出勤减少2.6天 vs 0.9天,家庭工作天数增加3.0天 vs 1.3天;改善维持至第96周。
要点
- 第24周塞妥珠单抗聚乙二醇组较安慰剂组每月缺勤减少1.0天 vs 0.4天,假性出勤减少2.6天 vs 0.9天。
- 第24周塞妥珠单抗聚乙二醇组较安慰剂组每月家庭工作天数增加3.0天 vs 1.3天。
- 强直性脊柱炎与非放射学中轴型脊柱关节炎亚组改善相似,且维持至第96周。
核心结论
- 与安慰剂相比,塞妥珠单抗聚乙二醇治疗显著改善中轴型脊柱关节炎患者的工作和家庭生产力,并带来更大的社会参与,可能带来可观的间接成本收益。
研究设计与样本
- RAPID-axSpA(NCT01087762)为III期双盲安慰剂对照试验,至第24周双盲、至第48周剂量盲、至第204周开放标签。
- 共325例中轴型脊柱关节炎患者按1:1:1随机接受安慰剂、塞妥珠单抗聚乙二醇200 mg每2周或400 mg每4周。
- 采用经验证的关节炎特异性工作生产力调查评估既往一个月内中轴型脊柱关节炎对工作、家庭生产力和社会活动参与的影响,数据展示至第96周。
- 治疗组间(安慰剂 vs 塞妥珠单抗聚乙二醇200 mg和400 mg剂量组合并)及亚组间比较采用非参数bootstrap-t法。
主要发现
- 基线时安慰剂组63.2%、塞妥珠单抗聚乙二醇组72.0%的患者在职。
- 至第24周,塞妥珠单抗聚乙二醇组患者每月平均缺勤减少1.0天、假性出勤减少2.6天,安慰剂组分别减少0.4天和0.9天。
- 至第24周,塞妥珠单抗聚乙二醇组患者每月平均增加家庭工作天数3.0天,安慰剂组为1.3天。
- 塞妥珠单抗聚乙二醇组患者报告家庭生产力下降天数或社会参与丧失天数更少。
- 强直性脊柱炎和非放射学中轴型脊柱关节炎亚组中观察到相似改善,且塞妥珠单抗聚乙二醇的改善维持至第96周。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the effect of certolizumab pegol (CZP) on work and household productivity, and on participation in family, social and leisure activities in patients with axial spondyloarthritis (axSpA), including ankylosing spondylitis (AS) and non-radiographic (nr-) axSpA. METHODS: RAPID-axSpA (NCT01087762) was a phase III, double-blind, placebo-controlled trial to week (Wk) 24, dose-blind to Wk48 and open-label to Wk204. A total of 325 patients were randomised 1:1:1 to placebo, CZP 200 mg Q2W or CZP 400 mg Q4W. The validated arthritis-specific Work Productivity Survey assessed the impact of axSpA on work and household productivity and participation in social activities during the preceding month. Data are shown to Wk96, with responses compared between treatment arms (placebo vs CZP 200 mg and 400 mg dose groups combined) and subpopulations using a non-parametric bootstrap-t method. RESULTS: At baseline, 63.2% of placebo and 72.0% of CZP patients were employed. By Wk24, CZP patients reported on average 1.0 fewer days of absenteeism and 2.6 fewer days of presenteeism per month, compared with 0.4 and 0.9 fewer days for placebo. At home, by Wk24, CZP patients reported on average 3.0 household work days gained per month versus 1.3 for placebo. CZP patients reported fewer days with reduced household productivity or days lost for social participation. Similar improvements were observed in AS and nr-axSpA subpopulations and improvements with CZP were maintained to Wk96. CONCLUSIONS: Compared with placebo, treatment with CZP significantly improved work and household productivity and resulted in greater social participation for patients with axSpA, which could lead to considerable indirect cost gains. TRIAL REGISTRATION NUMBER: NCT01087762.
引用
- van der Heijde D, Braun J, Rudwaleit M, et al. Improvements in workplace and household productivity with certolizumab pegol treatment in axial spondyloarthritis: results to week 96 of a phase III study. RMD Open. 2018. PMID: 29670761. doi:10.1136/rmdopen-2018-000659
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。